Fred Davenport, Jr. Sells 7,283 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Fred Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Medpace Stock Performance

Shares of MEDP stock opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15. The firm’s 50-day moving average is $550.16 and its 200-day moving average is $492.71.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in MEDP. AlphaGrep UK Ltd acquired a new position in Medpace in the 2nd quarter valued at $466,000. TD Waterhouse Canada Inc. lifted its holdings in shares of Medpace by 1,120.0% during the second quarter. TD Waterhouse Canada Inc. now owns 122 shares of the company’s stock worth $66,000 after buying an additional 112 shares in the last quarter. Nykredit A S bought a new stake in shares of Medpace in the second quarter valued at about $356,000. Symphony Financial Ltd. Co. bought a new stake in shares of Medpace in the second quarter valued at about $227,000. Finally, Proficio Capital Partners LLC boosted its position in shares of Medpace by 40.6% in the second quarter. Proficio Capital Partners LLC now owns 910 shares of the company’s stock valued at $482,000 after acquiring an additional 263 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on MEDP. TD Cowen boosted their target price on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.